EP1670749A1 - 2-substituted benzoic acid derivatives as hm74a receptor agonists - Google Patents

2-substituted benzoic acid derivatives as hm74a receptor agonists

Info

Publication number
EP1670749A1
EP1670749A1 EP04768088A EP04768088A EP1670749A1 EP 1670749 A1 EP1670749 A1 EP 1670749A1 EP 04768088 A EP04768088 A EP 04768088A EP 04768088 A EP04768088 A EP 04768088A EP 1670749 A1 EP1670749 A1 EP 1670749A1
Authority
EP
European Patent Office
Prior art keywords
nhc
compound
compound according
acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04768088A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mathew c/o GlaxoSmithKline Campbell
Richard Jonathan c/o GlaxoSmithKline Hatley
Jag Paul c/o GlaxoSmithKline HEER
Andrew McMurtrie c/o GlaxoSmithKline MASON
Neville Hubert c/o GlaxoSmithKline Nicholson
Ivan Leo c/o GlaxoSmithKline Pinto
Shahzad Sharooq c/o GlaxoSmithKline Rahman
Ian Edward David c/o GlaxoSmithKline Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1670749A1 publication Critical patent/EP1670749A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to therapeutically active compounds which are anthranilic acid derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under- activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial.
  • Dyslipidaemia is a general term used to describe individuals with aberrant lipoprotein profiles.
  • the main classes of compounds used for the treatment of patients with dyslipidaemia, and therefore at risk of cardiovascular disease are the statins, fibrates, bile-acid binding resins and nicotinic acid. Nicotinic acid (Niacin, a B vitamin) has been used clinically for over 40 years in patients with various forms of dyslipidaemia.
  • nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and reducing the number of cardiovascular events in several trials.
  • HSL hormone-sensitive triglyceride lipase
  • NEFA plasma non- esterified fatty acids
  • CETP cholesterol ester transfer protein
  • nicotinic acid produces a very desirable alteration in lipoprotein profiles; reducing levels of VLDL and LDL whilst increasing HDL. Nicotinic acid has also been demonstrated to have disease modifying benefits, reducing the progression and increasing the regression of atherosclerotic lesions and reducing the number of cardiovascular events in several trials.
  • WO 01/25190 A1 relates to diaryl amide derivatives and the use thereof as medicines.
  • WO 97/30019 A1 relates to aniline derivatives as antihyperglycemic or anti-diabetic compounds. It specifically discloses 2-(2-(((4-(phenyl)phenyl)amino)acetyl)amino) benzoic acid and 2-(2-(((4-phenyl)phenoxy)acetyl)amino)benzoic acid.
  • the present invention provides therapeutically active anthranilic acid derivatives and the use of these derivatives in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, in particular diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the compounds may also be of use in the treatment of inflammatory diseases or conditions, as set out further below.
  • the present invention provides a compound of Formula (I)
  • R 1 represents hydrogen, halogen or C C 3 alkyl
  • R 2 represents a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring
  • W represents a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring
  • n an integer selected from 2, 3 and 4;
  • p represents an integer selected from 0, 1 and 2;
  • q represents an integer selected from 1 , 2, 3 and 4;
  • R 3 represents hydrogen or methyl
  • R 4 and R 5 which may be the same or different, independently represent C C 3 alkyl
  • R 1 when R 1 is hydrogen, Z is -(CH 2 ) n -, and n is 2, then R 2 is other than para- chlorophenyl or para-methylphenyl;
  • a compound of Formula (I) is other than 2-(2-(((4-(phenyl)phenyl) amino)acetyl)amino)benzoic acid, 2-(2-(((4-phenyl)phenoxy)acetyl)amino) benzoic acid, 2-[[(4-cyclohexylphenoxy)acetyl]amino]benzoic acid, 2-[[3-[3-(4- chlorophenyl)-1 ,2,4-oxadiazol-5-yl]-1-oxopropyl]amino]benzoic acid or compound X
  • the R 2 ring system may be joined to the Z linker unit via either a ring carbon atom or via a ring heteroatom, where present.
  • R groups are hydrogen or C r C 3 alkyl, for example hydrogen or methyl.
  • R 2 is selected from pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, imidazolyl, oxazolyl and isoxazolyl.
  • R 2 is heterocyclic, R 2 is selected from pyrrolidinyl, imidazolidinyl, piperidinyl and morpholinyl.
  • R 2 is selected from cyclohexyl, phenyl, pyridinyl, pyrimidinyl, pyridazinyl and isoxazolyl.
  • the 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic R 2 groups may be substituted and thus include substituted cyclohexyl, substituted phenyl, substituted pyridine, substituted pyhmidine, substituted pyridazine or substituted isoxazole, in which the substituents are as defined further below.
  • R 2 is substituted phenyl
  • the substituents will be those defined for "aryl" substituents below.
  • the substituted phenyl bears one or two substituents selected from halogen C ⁇ - 3 alkyl (for example methylphenyl), Ci-ahaloalkyl (for example trifluoroalkyl including trifluoromethylphenyl), C ⁇ alkoxy (for example methoxyphenyl) and C ⁇ haloakloxy (for example trifluoroalkoxy including trifluoromethoxyphenyl).
  • the substituent is at the meta or para position, for example para.
  • R 2 represents doubly substituted phenyl
  • the substituents are at the para and meta, or at both meta positions.
  • R 2 is selected from the group consisting of:
  • Z represents -Y-W-X-, -(CH 2 ) q - ,
  • Y represents -O- , -CH 2 - or -CH 2 O-.
  • X is absent or represents -(CH 2 ) P SO 2 NR 3 -, -(CH 2 ) p NHC(O)- or - (CH 2 ) p NHC(O)NH-.
  • Y represents -CH 2 - X represents -(CH 2 ) p SO 2 NR 3 -.
  • Y represents -O- or - CH 2 O- X is absent.
  • W groups are 5 or 6 member aryl or heteroaryl rings.
  • W is aryl, for example C6 aryl (e.g. phenyl)
  • W is linked through the 1 and 4 or the 1 and 3 positions.
  • W is heteroaryl, for example a 5 member heteroaryl ring (e.g. 1 , 2, 4 oxadiazolyl)
  • W may be linked through the 3 and 5 positions.
  • W is heteroaryl, for example a 6 member heteroaryl ring (e.g. pyridinyl)
  • W may be linked through the 2 and 5 positions.
  • X is -(CH 2 ) p SO 2 NR 3 -, p is 0 and W is unsubstituted phenyl
  • W may for example be linked through the 1 and 4 (para) positions.
  • n 2
  • p represents an integer selected from 0 or 1.
  • W and R 2 each represent unsubstituted phenyl, whilst in other embodiments W represents unsubstituted phenyl and R 2 represents substituted phenyl.
  • alkyl refers to an optionally substituted straight or branched hydrocarbon chain containing the specified number of carbon atoms.
  • CrC 3 alkyl means a straight or branched hydrocarbon chain containing at least 1 and at most 3 carbon atoms. Examples of alkyl as used herein include, but are not limited to; methyl (Me), ethyl
  • alkoxy refers to an alkyl ether radical, wherein the term “alkyl” is defined above.
  • alkoxy as used herein include, but are not limited to; methoxy, ethoxy, n-propoxy, i-propoxy and the like.
  • alicyclic when used as a group or as part of a group refers to a cyclic hydrocarbon ring containing the specified number of carbon atoms.
  • aryl when used as a group or as part of a group refers to an aromatic hydrocarbon ring of the specified number of carbons. Examples of aryl as used herein include, but are not limited to, phenyl and benzyl.
  • heteroaryl when used as a group or as part of a group refers to an aryl group, as defined above, which contains one or more nitrogen or oxygen heteroatoms.
  • heteroaryl as used herein include, but are not limited to, pyridine, pyrimidine, pyridazine, imidazole, isoxazole, oxadiazoles and the like.
  • heterocyclic refers to an alicyclic group, as defined above, which contains one or more nitrogen or oxygen heteroatoms.
  • physiologically functional derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example an ester or an amide thereof, and includes any pharmaceutically acceptable salt, ester, or salt of such ester of a compound of Formula (I) which, upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) a compound of Formula (I) or an active metabolite or residue thereof.
  • the compounds of Formula (I) may be modified to provide physiologically functional derivatives thereof at any of the functional groups in the compounds, and that the compounds of Formula (I) may be so modified at more than one position.
  • the term "pharmaceutically acceptable” used in relation to an ingredient (active ingredient or excipient) which may be included in a pharmaceutical formulation for administration to a patient refers to that ingredient being acceptable in the sense of being compatible with any other ingredients present in the pharmaceutical formulation and not being deleterious to the recipient thereof.
  • solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula (I), a salt thereof or a physiologically functional derivative thereof) and a solvent.
  • solvents for the purposes of the present invention may not interfere with the biological activity of the solute.
  • suitable solvents include water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.
  • the solvent used is water, in which case the solvate may be referred to as a hydrate of the solute in question.
  • salt or solvate referred to above will be a pharmaceutically acceptable salt or solvate.
  • other salts or solvates may find use, for example, in the preparation of a compound of Formula (I) or in the preparation of a pharmaceutically acceptable salt or solvate thereof.
  • Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19.
  • Suitable pharmaceutically acceptable salts include acid addition salts formed from the addition of inorganic acids or organic acids, preferably inorganic acids. Examples of suitable acid addition salts include hydrochlorides, hydrobromides, sulphates and acetates.
  • compositions include those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.
  • Suitable pharmaceutically acceptable salts also include alkali metal salts formed from the addition of alkali metal bases such as alkali metal hydroxides.
  • An example of a suitable alkali metal salt is a sodium salt.
  • the present invention provides the use of a compound of Formula (la)
  • R 1 represents hydrogen, halogen or C C 3 alkyl
  • R 2 represents a 5 or 6-member aryl, heteroaryl, or heterocyclic or alicyclic ring
  • W represents a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring
  • p represents an integer selected from 0, 1 and 2;
  • q represents an integer selected from 1 , 2, 3 and 4;
  • R 3 represents hydrogen or methyl
  • R 4 and R 5 which may be the same or different, independently represent C C 3 alkyl.
  • the R 2 ring system may be joined to the Z linker unit via either a ring carbon atom or via a ring heteroatom, where present.
  • R 1 groups are hydrogen or CrC 3 alkyl, for example hydrogen or methyl.
  • R 2 is selected from pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrazolyl, imidazolyl, oxazolyl and isoxazolyl.
  • R 2 is heterocyclic, R 2 is selected from pyrrolidinyl, imidazolidinyl, piperidinyl and morpholinyl.
  • R 2 is selected from cyclohexyl, phenyl, pyridinyl, pyrimidinyl, pyridazinyl and isoxazolyl.
  • the 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic R 2 groups may be substituted and thus include substituted cyclohexyl, substituted phenyl, substituted pyridine, substituted pyrimidine, substituted pyridazine or substituted isoxazole, in which the substituents are as defined above.
  • R 2 is substituted phenyl
  • the substituents will be those defined for "aryl" substituents above.
  • the substituted phenyl bears one or two substituents selected from halogen C ⁇ alkyl (for example methylphenyl), C ⁇ haloalkyl (for example trifluoroalkyl including trifluoromethylphenyl), C- ⁇ _ 3 alkoxy (for example methoxyphenyl) and C ⁇ haloakloxy (for example trifluoroalkoxy including trifluoromethoxyphenyl).
  • R 2 represents singly substituted phenyl
  • the substituent is at the meta or para position, for example para.
  • the substituents are at the para and meta, or at both meta positions.
  • R 2 is selected from the group consisting of:
  • Z represents -Y-W-X-, -(CH 2 ) q - , -(CH 2 ) n O- or - (CH 2 ) p NHC(O)-.
  • Y represents -O- , -CH 2 - or -CH 2 O-.
  • X is absent or represents -(CH 2 ) p SO 2 NR 3 -, -(CH 2 ) p NHC(O)- or - (CH 2 ) p NHC(O)NH ⁇ .
  • Y represents -CH 2 -
  • X represents -(CH 2 ) p SO 2 NR 3 -.
  • Y represents -O- or - CH 2 O- X is absent.
  • W groups are 5 or 6 member aryl or heteroaryl rings.
  • W is aryl, for example C6 aryl (e.g. phenyl)
  • W is linked through the 1 and 4 or the 1 and 3 positions.
  • W is heteroaryl, for example a 5 member heteroaryl ring (e.g. 1 , 2, 4 oxadiazolyl)
  • W may be linked through the 3 and 5 positions.
  • W is heteroaryl, for example a 6 member heteroaryl ring (e.g. pyridinyl)
  • W may be linked through the 2 and 5 positions.
  • X is -(CH 2 ) p SO 2 NR 3 -, p is 0 and W is unsubstituted phenyl
  • W may for example be linked through the 1 and 4 (para) positions.
  • n 2
  • p represents an integer selected from 0 or 1.
  • W and R 2 each represent unsubstituted phenyl, whilst in other embodiments W represents unsubstituted phenyl and R 2 represents substituted phenyl.
  • This aspect of the invention also provides the use of a compound of Formula (I)
  • this aspect of the present invention includes, with respect to the use of compounds of Formula (I) or of Formula (la) in the manufacture of a medicament, any combination of particular embodiments and covers all combinations of particular substituents of compounds of Formula (I) or of Formula (la) described hereinabove.
  • Compounds of the present invention are of potential therapeutic benefit in the treatment and amelioration of the symptoms of many diseases of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • the use of a compound of Formula (la) in the treatment of one or more of these diseases is a further aspect of the present invention.
  • Inflammation represents a group of vascular, cellular and neurological responses to trauma. Inflammation can be characterised as the movement of inflammatory cells such as monocytes, neutrophils and granulocytes into the tissues. This is usually associated with reduced endothelial barrier function and oedema into the tissues. Inflammation with regards to disease typically is referred to as chronic inflammation and can last up to a lifetime. Such chronic inflammation may manifest itself through disease symptoms. The aim of anti-inflammatory therapy is therefore to reduce this chronic inflammation and allow for the physiological process of healing and tissue repair to progress.
  • a further aspect of the present invention resides in the use of a compound of Formula (la) or a salt, solvate or physiologically functional derivative thereof as defined above in the treatment of inflammatory diseases or conditions of the joint, particularly arthritis (e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure), or the gastrointestinal tract (e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting from infection, the enteropathy provoked by non-steroidal anti-inflammatory drugs), of the lung (e.g. adult respiratory distress syndrome, asthma, cystic fibrosis, or chronic obstructive pulmonary disease), of the heart (e.g.
  • arthritis e.g. rheumatoid arthritis, osteoarthritis, prosthetic joint failure
  • the gastrointestinal tract e.g. ulcerative colitis, Crohn's disease, and other inflammatory bowel and gastrointestinal diseases, gastritis and mucosal inflammation resulting
  • myocarditis of nervous tissue (e.g. multiple sclerosis), of the pancreas, (e.g. inflammation associated with diabetes melitus and complications thereof), of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, eczema, urticaria, burn injury), of the eye (e.g. glaucoma) as well as of transplanted organs (e.g. rejection) and multi-organ diseases (e.g.
  • systemic lupus erythematosis, sepsis systemic lupus erythematosis, sepsis
  • the compounds of Formula (la) are useful in the treatment and prevention of inflammation, and cardiovascular diseases or conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.
  • a compound of Formula (la) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof in the manufacture of a medicament for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds are also provided for use in the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • Nicotinic acid has a significant side effect profile, possibly because it is dosed at high level (gram quantities daily). The most common side effect is an intense cutaneous flushing.
  • the compounds of the present invention preferably exhibit reduced side effects compared to nicotinic acid.
  • HM74A has been identified as a high affinity receptor for nicotinic acid whilst HM74 is a lower affinity receptor.
  • the compounds of the present invention are selective for HM74A by which is meant that they show greater affinity for HM74A than for HM74.
  • HEK293T cells HEK293 cells stably expressing the SV40 large T-antigen
  • DMEM fetal calf serum
  • 2mM glutamine 10% foetal calf serum
  • Cells were seeded in 90mm culture dishes and grown to 60-80% confluence (18-24h) prior to transfection.
  • Human HM74A GenBankTM accession number AY148884
  • pcDNA3 mammalian expression vector
  • CHO-K1 cells For generation of stable cell lines the above method was used to transfect CHO-K1 cells seeded in six well dishes grown to 30% confluence. These cells were maintained in DMEM F-12 HAM media containing 10% foetal calf serum and 2mM glutamine. 48h post-transfection the media was supplemented with 400 ⁇ g/ml Geneticin (G418, Gibco) for selection of antibiotic resistant cells. Clonal CHO-K1 cell lines stably expressing
  • HM74A were confirmed by [ 35 S]-GTP ⁇ S binding measurements, following the addition of nicotinic acid.
  • P2 membrane preparation - Plasma membrane-containing P2 particulate fractions were prepared from cell pastes frozen at -80°C after harvest. All procedures were carried out at 4°C. Cell pellets were resuspended in 1 ml of 10mM Tris-HCI and 0.1 mM EDTA, pH 7.5 (buffer A) and by homogenisation for 20s with a Ultra Turrax followed by passage (5 times) through a 25-gauge needle. Cell lysates were centrifuged at 1 ,000g for 10 min in a microcentrifuge to pellet the nuclei and unbroken cells and P2 particulate fractions were recovered by microcentrifugation at 16,000g for
  • membranes (10 ⁇ g per point) were diluted to 0.083 mg/ml in assay buffer (20 mM HEPES, 100 mM NaCI, 10 mM MgCI 2 , pH7.4) supplemented with saponin (10 mg/l) and pre-incubated with 10 ⁇ M GDP.
  • Assay buffer 20 mM HEPES, 100 mM NaCI, 10 mM MgCI 2 , pH7.4
  • saponin 10 mg/l
  • Various concentrations of nicotinic acid or related molecules were added, followed by [ 35 S]-GTP ⁇ S (1170 Ci/mmol, Amersham) at 0.3 nM (total vol. of 100 ⁇ l) and binding was allowed to proceed at room temperature for 30 min. Non-specific binding was determined by the inclusion of 0.6 mM GTP.
  • Wheatgerm agglutinin SPA beads (Amersham) (0.5 mg) in 25 ⁇ l assay buffer were added and the whole was incubated at room temperature
  • 384-well format Briefly, the dilution of standard or test compounds were prepared and added to a 384-well plate in a volume of 10 ⁇ l. Membranes (HM74A or HM74) were diluted in assay buffer (20mM HEPES, 100mM NaCI, 10mM MgCI 2 , pH7.4) supplemented with saponin (60 ⁇ g/ml), Leadseeker WGA beads (Amersham; 250 ⁇ g/well) and 10 ⁇ M GDP, so that the 20 ⁇ l volume added to each well contains 5 ⁇ g of membranes. [ 35 S]-GTP ⁇ S (1170 Ci/mmol, Amersham) was diluted (1 :1500) in assay buffer and 20 ⁇ l added to each well.
  • the plates were sealed, pulse spun and incubated for 4hours at room temperature. At the end of the incubation period the plates were read on a Leadseeker machine (VIEWLUX PLUS; Perkin-Elmer) to determine the levels of specific binding.
  • HM74A agonists are tested in male Spague-Dawley rats (200-250grammes) which have been fasted for at least 12 hours prior to the study.
  • the compounds are dosed intravenously (5ml/kg) or by oral gavage (10ml/kg).
  • Blood samples (0.3ml tail vein bleed) are taken pre-dose and at three times post-dose (times ranging from 1 ⁇ minutes to 8 hours post-dose). Each blood sample is transferred to a heparin tube (Becton Dickinson Microtainer, PST LH) and centrifuged (10,000 g for 5 minutes) to produce a plasma sample.
  • heparin tube Becton Dickinson Microtainer, PST LH
  • NEFA non-esterified fatty acids
  • Nicotinic acid is used as positive control.
  • Male Dunkin Hartley guinea pigs (300-800g) are fasted for 12 hours prior to being anaesthetised with a mixture of Ketamine hydrochloride (Vetalar, 40mg/kg i.m.), Xylazine (Rompun, 8mg/kg i.m.) and sodium pentobarbitone (Sagatal, 30mg/kg i.p.).
  • a tracheostomy is performed and the animals are mechanically ventilated with room air (10-12mL/kg, 60 breaths/min).
  • room air (10-12mL/kg, 60 breaths/min).
  • a jugular vein, and a carotid artery are cannulated for intravenous administration of test compound and collection of blood respectively.
  • An infra-red temperature probe (Extech Instruments) is placed 3-5mm from the tip of the left ear. Temperature measurements are recorded every minute from 5 minutes prior to test compound or nicotinic acid and up to 40 minutes post-administration of test compound or nicotinic acid. Data is automatically collected on a Psion computer before being transferred for data analysis within an Excel spreadsheet.
  • a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof for use in human or veterinary medicine, particularly in the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.
  • the compounds may also find favour as therapeutics for coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease and stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • references herein to treatment extend to prophylaxis, prevention of recurrence and suppression of symptoms as well as the treatment of established conditions.
  • a method for the treatment of a human or animal subject with a condition in which under-activation of the HM74A receptor contributes to the condition or in which activation of the receptor will be beneficial comprises administering to said human or animal subject an effective amount of a compound of Formula (I) or a physiologically acceptable salt or solvate thereof.
  • the present invention provides a method for the treatment of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, or hypertriglyceridaemia which method comprises administering to said human or animal subject an effective amount of a compound of Formula (la) or a physiologically acceptable salt or solvate thereof.
  • disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, or hypertriglyceridaemia
  • the invention also provides methods for the treatment of coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity which methods comprise administering to said human or animal subject an effective amount of a compound of Formula (I) or a physiologically acceptable salt, solvate or derivative thereof.
  • the amount of a HM74A modulator which is required to achieve the desired biological effect will, of course, depend on a number of factors, for example, the mode of administration and the precise clinical condition of the recipient.
  • the daily dose will be in the range of 0.1 mg - 1g/kg, typically 0.1 - 100mg/kg.
  • An intravenous dose may, for example, be in the range of 0.01 mg to 0.1g/kg, typically 0.01 mg to
  • 10mg/kg which may conveniently be administered as an infusion of from 0.1 ⁇ g to 1 mg, per minute.
  • Infusion fluids suitable for this purpose may contain, for example, from 0.01 ⁇ g to 0.1 mg, per millilitre.
  • Unit doses may contain, for example, from 0.01 ⁇ g to 1g of a HM74A modulator.
  • ampoules for injection may contain, for example, from 0.01 ⁇ g to 0.1 g and orally administrable unit dose formulations, such as tablets or capsules, may contain, for example, from 0.1 mg to 1g. No toxicological effects are indicated/expected when a compound of the invention is administered in the above mentioned dosage range.
  • a compound of the present invention may be employed as the compound perse in the treatment of a the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, but is preferably presented with an acceptable carrier in the form of a pharmaceutical formulation.
  • the carrier must, of course, be acceptable in the sense of being compatible with the other ingredients of the formulation and must not be deleterious to the recipient.
  • the carrier may be a solid or a liquid, or both, and is preferably formulated with the HM74A modulator as a unit-dose formulation, for example, a tablet, which may contain from 0.05% to 95% by weight of the HM74A modulator.
  • the formulations include those suitable for oral, rectal, topical, buccal (e.g. sub- lingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration.
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges or tablets, each containing a predetermined amount of a HM74A modulator; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • the formulations are prepared by uniformly and intimately admixing the active HM74A modulator with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • a tablet may be prepared by compressing or moulding a powder or granules of the HM74A modulator optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent and/or surface active/dispersing agent(s).
  • Moulded tablets may be made by moulding, in a suitable machine, the powdered compound moistened with an inert liquid diluent.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono- oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl ⁇ -hydroxybenzoates or sorbic acid.
  • the preparations may also contain buffer salts, flavouring, colouring and/or sweetening
  • Formulations suitable for buccal (sub-lingual) administration include lozenges comprising a HM74A modulator in a flavoured base, usually sucrose and acacia or tragacanth, and pastilles comprising the HM74A modulator in an inert base such as gelatin and glycerin or sucrose and acacia.
  • Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of an HM74A modulator, preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also be effected by means of subcutaneous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the HM74A modulator with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions according to the invention will generally contain from 0.1 to 5% w/w of the HM74A modulator.
  • formulations of the present invention suitable for parenteral administration comprising a compound according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multi-dose containers with an added preservative.
  • the compositions may take such forms as solutions, suspensions, or emulsions in aqueous or non- aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or toxicity adjusting agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • the dry solid presentation may be prepared by filling a sterile powder aseptically into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.
  • Formulations suitable for rectal administration are preferably presented as unit-dose suppositories. These may be prepared by admixing a HM74A modulator with one or more conventional solid carriers, for example, cocoa butter or glycerides and then shaping the resulting mixture.
  • Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which may be used include vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the HM74A modulator is generally present at a concentration of from 0.1 to 15% w/w of the composition, for example, from 0.5 to 2%.
  • topical administration as used herein, we include administration by insufflation and inhalation.
  • preparation for topical administration include ointments, creams, lotions, powders, pessaries, sprays, aerosols, capsules or cartridges for use in an inhaler or insufflator or drops (e.g. eye or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents and/or solvents.
  • bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil or a solvent such as a polyethylene glycol.
  • Thickening agents which may be used include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, microcrystalline wax and beeswax.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
  • Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch.
  • Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.
  • Spray compositions may be formulated, for example, as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, with the use of a suitable propellant, e.g.
  • dichlorodifluoromethane trichlorofluoromethane, dichlorotetrafluoroethane, 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, 1 ,1 ,1 ,2- tetrafluorethane, carbon dioxide or other suitable gas.
  • Capsules and cartridges for use in an inhaler or insufflator, of for example gelatin may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • compositions according to the invention may also be used in combination with other therapeutic agents, for example in combination with other classes of dyslipidaemic drugs (e.g. statins, fibrates, bile-acid binding resins or nicotinic acid).
  • dyslipidaemic drugs e.g. statins, fibrates, bile-acid binding resins or nicotinic acid.
  • the compounds of the instant invention may be used in combination with one or more other therapeutic agents for example in combination with other classes of dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid.
  • dyslipidaemic drugs e.g. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates or bile acid binding resins or nicotinic acid.
  • the invention thus provides, in a further aspect, the use of such a combination in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial and the use of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof in the manufacture of a medicament for the combination therapy of disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, or hypertriglyceridaemia, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, as well as the cardiovascular indications associated with type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity.
  • disorders of lipid metabolism including dislipidaemia or hyperlipoproteinaemia such as diabetic dyslipidaemia and mixed
  • the compounds of the present invention are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
  • compositions comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the two components When combined in the same formulation it will be appreciated that the two components must be stable and compatible with each other and the other components of the formulation and may be formulated for administration.
  • When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.
  • each component When in combination with a second therapeutic agent active against the same disease, the dose of each component may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
  • the invention thus provides, in a further aspect, a combination comprising a compound of Formula (I) or a physiologically acceptable salt or solvate thereof together with another therapeutically active agent.
  • the combination may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof represent a further aspect of the invention.
  • the compounds of the Formula (I) have useful duration of action.
  • R 1 represents hydrogen
  • Z represents -Y-W-X-
  • Y represents -(CH 2 ) p O- p represents the integer 1
  • W, X and R 2 are as defined above is set out in scheme (a):
  • the present invention provides a process for preparing a compound of Formula (I) or of Formula (la) comprising:
  • step (ii) comprises addition of W and a further step (ii)(a), addition of R 2 , is included in the form of a further substitution reaction.
  • steps (ii) and (iii) of Method A may be used to prepare compounds of the invention in which Z represents -(CH 2 ) n O- n is 1 and R 2 represents aryl, and is set out in scheme (a-iii).
  • R represents -Z-R 2 as defined above.
  • the present invention provides a process for preparing a compound of
  • step (d) of scheme (b-v) A further example of a process according to Method B, for preparation of compounds in which Z is Y-W-X is set out below as step (d) of scheme (b-v). Steps (a) to (c) of scheme (b-v) produce the R-CO 2 H starting material of scheme (b) above.
  • Methyl anthranilate (0.85 ml, 6.6 mmole, 1 equiv) and chloroacetyl chloride (0.63 ml, 7.9 mmole, 1.2 equiv) were stirred vigorously in a mixture of THF (10 ml) and water (10 ml) and cooled to 4°C while a 2M solution of NaOH (3.3 ml) was slowly added.
  • 3-Methoxyphenylboronic acid (44.4 mg, 0.29 mmole, 1.2 equiv), Cs 2 CO 3 (325 mg, 1 mmole, 4 equiv) and 2-[2-(4-lodo-phenoxy)ethanoylamino]-benzoic acid methyl ester (100 mg, 0.24 mmole, 1 equiv) were dissolved in THF / water (5/1 , 25 ml) and degassed by bubbling a stream of argon through the solution for 25 minutes.
  • Tetrakistriphenylphosphine palladium (5.8 mg, 0.005 mmole, 0.02equiv) was added and the reaction mixture was heated for 18 hours at 80°C under an atmosphere of argon.
  • reaction mixture was treated with ethanol (5 ml) and water (5 ml), basified with 2M
  • Example 6 ⁇ H (400MHz, DMSO-d6) 4.80 (2H, s), 7.17 -7.20 (3H, m), 7.37 -
  • Methyl (2-chloroacetyl)anthranilate (0.5 g, 2.2 mmole, 1 equiv), 4-phenylphenol (0.45 g, 2.64 mmole, 1.2 equiv) and potassium carbonate (0.456 g, 3.3 mmole, 1.5 equiv) were heated to 90°C in DMF (10 ml) for 6 hours.
  • Methyl (4-phenylphenoxy)acetylanthranilate (153 mg, 0.42 mmole, 1 equiv) was dissolved in a mixture of water and ethanol (2 : 1 , 10 ml) and the solution was heated to reflux with 2M NaOH solution (0.23 ml, 0.46 mmole, 1.1 equiv) overnight.
  • Polystyrene-supported 1 ,5,7-triazabicyclo[4.4.0]dec-5-ene [Fluka AG, crosslinked with 2% 1 ,4-divinylbenzene, loading 2.6 mmol/g] (0.115g, 0.3mmol) was treated with a solution of 3,4-dichlorophenol (0.048g, 0.15mmol) in acetonitrile (0.5ml).
  • the mixture was stirred and heated to 45°C for 2 hours then stirred at ambient temperature for 18 hours.
  • the mixture was acidified to about pH4 by the addition of 2M aqueous hydrochloric acid and the precipitated product filtered and dried to afford the title compound (0.0106g, 25%) as a white solid.
  • Example 21 ⁇ H (400MHz, DMSO-d6) 2.74 (2H, t), 2.84 (2H, t), 7.14(1 H, t), 7.27 (1 H, t), 7.46 (2H,t), 7.58 (1H, t), 7.63 (1H, s), 7.75 (2H, d), 7.96 (1H, d), 8.33 (1H, s), 8.50 (1H, d), 11.16 (1H, br.s), 13.30 (1H, br.s); m/z 334.04 [M-H + ].
  • Example 22 ⁇ H (400MHz, MeOH) 2.65 (2H, t), 2.92 (2H, t), 6.68 (2H, d), 7.05 (2H, d), 7.12 (1H, br.s), 7.51 (1H, t), 8.06 (1H, br.s), 8.54 (1H, d); m/z 283.97 [M-H + ].
  • Example 23 ⁇ H (400MHz, DMSO-d6) 3.03 (2H, t), 3.27 (2H, t), 3.83 (3H, s), 7.08 (2H, d), 7.14 (1H, t), 7.56 (1H, t), 7.92 (2H, d), 7.98 (1H, d), 8.41 (1H, d), 11.30 (1H, br.s), 13.55 (1H, br.s); m/z 365.97 [M-H + ].
  • Example 24 ⁇ H (400MHz, DMSO-d6) 3.05 (2H, t), 3.31 (2H, t), 7.13 (1H, t), 7.57 (1H, t), 7.63 (2H, d), 7.98 (3H, m), 8.40 (1H, d), 11.30 (1H, br.s), 13.55 (1H, br.s); m/z 370.20 [M-H + ].
  • Example 25 ⁇ H (400MHz, DMSO-d6) 2.14 (2H, m), 2.58 (2H, t), 3.10 (2H, t), 7.11 (1H, t), 7.55 (1H, t), 7.63 (2H, d), 7.95 (1H, d), 7.98 (2H, d), 8.43 (1H, d), 11.15 (1H, br.s), 13.40 (1H, br.s); m/z 383.41 [M-H + ].
  • Example 26 ⁇ H (400MHz, DMSO-d6) 2.75 (2H, t), 2.94 (2H, t), 7.13 (1H, t), 7.29 (1H, d), 7.52 (1H, d), 7.56 (2H, m), 7.96 (1H, d), 8.44 (1H, d), 11.11 (1H, br.s), 13.35 (1H, br.s); m/z 337.91 [M-H + ].
  • Example 27 ⁇ H (400MHz, DMSO-d6) 6.92 (1H, d), 7.18 (1H, t), 7.40 (1H, t), 7.50 (2H, t), 7.62 (1H, t), 7.68 (1H, d), 7.74 (4H, m), 7.83 (2H, m), 8.03 (1H, d), 8.60 (1H, d), 11.45 (1H, br.s); m/z 343.88 [M-H + ].
  • Example 30 ⁇ H (400MHz, DMSO-d6) 2.90 (3H, s), 3.90 (2H, s), 7.19 (1H, t), 7.45 (1H, m), 7.51 (2H, t), 7.60 (1H, t), 7.75 (2H, d), 7.93 (4H, s), 8.02 (1H, d), 8.59 (1H, d), 12.00 (1H, br.s); m/z 425.00 [M+H + ].
  • Example 33 2-( ⁇ 3-r5-(2-fluorophenyl)-2 -/-tetrazol-2-vnpropanoyllamino)benzoic acid
  • To 3-[5-(2-fluorophenyl)-2H-tetrazol-2-yl]propanoic acid (115mg, 0.66mmol) in THF (5ml) was added carbonyl diiimidazole (110mg, 0.68mmol) and the solution stirred for 1h.
  • Anthranilic acid 90mg, 0.66mmol was added to the solution followed by pyridine tosylate (410mg, 1.64mmol). The mixture was heated at 70°C for 18h, cooled, filtered and concentrated.
  • 2,5-dibromopyridine (10g, 42.2mmol, 1 equiv) was stirred vigorously in DMF and cooled to -10°C (salted ice bath) and NaH (60% suspension in mineral oil, 2.6g, 65.0mmol, L ⁇ equiv) was added in five portions.
  • Methyl glycolate (1.8ml, 46.6mmol, Llequiv) was added dropwise, and the reaction mixture allowed to warm to room temperature for 16 hr under an atmosphere of nitrogen.
  • reaction mixture was treated with water (1ml) and K 2 CO 3 (0.040g, 0.3mmol, 3equiv) and heated at 90°C for 4 hr. After cooling, the reaction mixture was acidified with 2N HCI and the resulting solid filtered then purified by preparative h.p.l.c.
  • the aqueous phase was extracted with further ethyl acetate (100ml) and the organic fractions were combined, dried over magnesium sulfate, filtered and evaporated.
  • the product was purified by chromatography using KP SilTM silica (32-63um, 60A, 90g) and eluting using a gradient from ethyl acetate/cyclohexane @ 2:1 to ethyl acetate and then to ethyl acetate/methanol @
  • Example 64 2-( ⁇ [5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]acetyl ⁇ amino)benzoicacid NMR ⁇ H (400MHz, d 6 -DMSO) 1.01-1.14(m, 2H), 1.36-1.64(m, 4H), 1.64-1.82(m, 5H),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04768088A 2003-08-14 2004-08-13 2-substituted benzoic acid derivatives as hm74a receptor agonists Withdrawn EP1670749A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0319124.4A GB0319124D0 (en) 2003-08-14 2003-08-14 Chemical compounds
PCT/GB2004/003528 WO2005016870A1 (en) 2003-08-14 2004-08-13 2-substituted benzoic acid derivatives as hm74a receptor agonists

Publications (1)

Publication Number Publication Date
EP1670749A1 true EP1670749A1 (en) 2006-06-21

Family

ID=28052522

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04768088A Withdrawn EP1670749A1 (en) 2003-08-14 2004-08-13 2-substituted benzoic acid derivatives as hm74a receptor agonists

Country Status (4)

Country Link
EP (1) EP1670749A1 (enExample)
JP (1) JP2007502264A (enExample)
GB (1) GB0319124D0 (enExample)
WO (1) WO2005016870A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11613542B2 (en) 2017-08-15 2023-03-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
JP5010917B2 (ja) * 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
JP2008520715A (ja) * 2004-11-23 2008-06-19 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、そのような化合物を含む組成物、および治療方法
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US20080221108A1 (en) * 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0503053D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503054D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
JP2008536846A (ja) * 2005-04-13 2008-09-11 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、かかる化合物を含有する組成物及び治療方法
KR100955112B1 (ko) 2005-06-14 2010-04-28 에프. 호프만-라 로슈 아게 안트라닐산 유도체
SI1901731T1 (sl) * 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
WO2007027532A2 (en) * 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
JP2009508952A (ja) * 2005-09-20 2009-03-05 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
JP2009520820A (ja) * 2005-12-20 2009-05-28 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、前記化合物を含む組成物及び治療方法
KR101384572B1 (ko) * 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
US8633160B2 (en) 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
WO2007092364A2 (en) * 2006-02-07 2007-08-16 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2648642A1 (en) * 2006-04-11 2007-10-25 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2008016676A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2008069611A1 (en) * 2006-12-08 2008-06-12 Korea Research Institute Of Chemical Technology N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same
KR100832750B1 (ko) 2006-12-08 2008-05-27 한국화학연구원 Ｎ-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물
WO2008144423A2 (en) * 2007-05-15 2008-11-27 Medical College Of Georgia Research Institute, Inc. Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer
EP2195328A4 (en) 2007-08-15 2011-06-15 Cytokinetics Inc PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
US8415479B2 (en) 2008-03-31 2013-04-09 Renascience Co., Ltd. Inhibitor of plasminogen activator inhibitor-1
EP2607348B8 (en) * 2009-03-31 2021-04-21 Renascience Inc. Plasminogen Activator Inhibitor-1 Inhibitor
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
WO2012034116A2 (en) * 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2013092786A1 (en) * 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
WO2014171464A1 (ja) 2013-04-15 2014-10-23 株式会社レナサイエンス Ｐａｉ－１阻害剤の新規用途
CN104418764B (zh) * 2013-09-11 2017-02-01 上海伊明化学科技有限公司 一种二氢燕麦酰基邻氨基苯甲酸d合成方法
ES2578377B1 (es) 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.
CN106511110B (zh) * 2016-10-25 2019-10-01 福州美乐莲生物科技有限公司 二氢燕麦生物碱d盐类化合物作为化妆品活性成分的应用及其合成方法
EP3662908A1 (en) * 2018-12-04 2020-06-10 Consejo Superior de Investigaciones Cientificas (CSIC) Modulating compounds of kchip2 and its use for the treatment of cardiovascular pathologies
CN109553550B (zh) * 2018-12-29 2022-02-22 上海克琴科技有限公司 一种合成二氢燕麦生物碱的方法
CN112939803B (zh) * 2021-02-07 2023-07-18 郑州轻工业大学 一种二氢燕麦生物碱d的制备工艺
CN114478296B (zh) * 2022-02-14 2024-07-19 河南旭瑞新材料科技有限公司 一种二氢燕麦生物碱的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024669A1 (de) * 1979-08-27 1981-03-11 BASF Aktiengesellschaft Substituierte N-Benzoylanthranilsäurederivate und deren Anhydroverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Mittel dafür
EP0324377A2 (en) * 1988-01-07 1989-07-19 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids
EP0806412A1 (en) * 1995-11-27 1997-11-12 Teijin Limited Benzene derivatives
WO1999007670A1 (en) * 1997-08-05 1999-02-18 American Home Products Corporation Anthranilic acid analogs
WO2000027823A1 (en) * 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
WO2000040247A1 (en) * 1999-01-08 2000-07-13 Alizyme Therapeutics Limited 2-oxy-benzoxazinone derivatives for the treatment of obesity
EP1101755A1 (en) * 1998-07-24 2001-05-23 Teijin Limited Anthranilic acid derivatives
EP1256341A1 (en) * 2000-02-15 2002-11-13 Teijin Limited Cancer remedy comprising anthranilic acid derivative as active ingredient
WO2003006443A2 (de) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59122449A (ja) * 1982-12-28 1984-07-14 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6097946A (ja) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd カルボキサミド誘導体
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
CN1273579A (zh) * 1997-08-05 2000-11-15 美国家用产品公司 氨茴酸类似物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024669A1 (de) * 1979-08-27 1981-03-11 BASF Aktiengesellschaft Substituierte N-Benzoylanthranilsäurederivate und deren Anhydroverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Mittel dafür
EP0324377A2 (en) * 1988-01-07 1989-07-19 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids
EP0806412A1 (en) * 1995-11-27 1997-11-12 Teijin Limited Benzene derivatives
WO1999007670A1 (en) * 1997-08-05 1999-02-18 American Home Products Corporation Anthranilic acid analogs
EP1101755A1 (en) * 1998-07-24 2001-05-23 Teijin Limited Anthranilic acid derivatives
WO2000027823A1 (en) * 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
WO2000040247A1 (en) * 1999-01-08 2000-07-13 Alizyme Therapeutics Limited 2-oxy-benzoxazinone derivatives for the treatment of obesity
EP1256341A1 (en) * 2000-02-15 2002-11-13 Teijin Limited Cancer remedy comprising anthranilic acid derivative as active ingredient
WO2003006443A2 (de) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005016870A1 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11613542B2 (en) 2017-08-15 2023-03-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds

Also Published As

Publication number Publication date
GB0319124D0 (en) 2003-09-17
WO2005016870A1 (en) 2005-02-24
JP2007502264A (ja) 2007-02-08

Similar Documents

Publication Publication Date Title
EP1670749A1 (en) 2-substituted benzoic acid derivatives as hm74a receptor agonists
US20080139565A1 (en) Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia
AU2003297232B2 (en) 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
CN101863888B (zh) 具有hm74a受体活性的药物
EP1853579A2 (en) 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
AU2004277947A1 (en) 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
EP1689699A2 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
WO2004048349A1 (en) Farnesoid x receptor agonists
WO2004103279A2 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
JP2010514831A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514829A (ja) ピペリジンｇｐｃｒアゴニスト
MXPA06002435A (es) Compuesto activador del receptor activado por el proliferador de peroxisoma y composicion farmaceutica que lo contiene.
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
WO2006085112A1 (en) Anthranilic acid derivatives as hm74a receptor agonists
WO2004072050A1 (en) Heterocyclic compounds useful as nurr-1 activators
US20080312220A1 (en) Oxadiazole Derivatives with Crth2 Receptor Activity
WO2009147121A1 (en) Carboxyl substituted indoles for use as ppar alpha modulators
WO2006085111A1 (en) Anthranilic acid derivatives active at the hm74a receptor
CN105164112B (zh) 酰胺类化合物及其制备方法、药物组合物和用途
CN101274934A (zh) 具有hm74a受体活性的药物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

17Q First examination report despatched

Effective date: 20060912

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060209

Extension state: LT

Payment date: 20060209

Extension state: HR

Payment date: 20060209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090205